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INTRODUCTION
Endoscopic sphincterotomy (EST) using endoscopic retro-
grade cholangiopancreatography (ERCP) is currently the pri-
mary treatment in removing common bile duct (CBD) stones, 
with more than 90% of success rate.
1-3 However, endoscopic 
stone extraction is not easy when the stones are big or placed 
above a stricture. Since the introduction of endoscopic papil-
lary large balloon dilation (EPLBD) after limited EST by Ersoz 
Clin Endosc  2011;44:123-128
  Copyright © 2011 The Korean Society of Gastrointestinal Endoscopy  123
et al.
4 the combination of EPLBD plus EST is being applied 
to the removal of CBD stones unmanageable with conven-
tional methods.
The recurrence rate of bile duct stones after EST is estimat-
ed around 5% to 21%, which is reported to be associated with 
several factors.
1,5-8 There are few studies, however, reporting fac-
tors associated with the recurrence of CBD stones after EPLBD. 
This study was conducted to determine the short-term follow-
up results, especially the recurrence data, in patients who re-
ceived EPLBD plus limited EST or EPLBD alone. 
MATERIALS AND METHODS
Patients
The study was performed in patients whose radiologic im-
aging data (abdominal ultrasonography, abdominal computed 
tomography [CT], and magnetic resonance cholangiopan-
creatography) were available, among those who visited Ga-
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chon University Gil Hospital for CBD stone removal between 
September 2008 and February 2010, and was followed for at 
least 6 months after EPLBD with limited EST or EPLBD alone. 
Exclusion criteria were follow-up without imaging studies, 
history of stone removal with EPLBD, surgery due to the fail-
ure of endoscopic stone extraction, and concomitant pancre-
atobiliary cancer. Eligible patients were followed with CT at 6 
months after the EPLBD alone or EPLBD with limited EST. 
Patients were treated again with EPLBD only or in combina-
tion with the limited EST, in case stones were detected during 
the follow-up in some cases, recurrent stones were treated by 
Dormia baskets or retrieval balloon without EPLBD or EST. 
CTs were performed at 6 months interval after the removal of 
stones or when symptoms occur. 
A total of 141 patients were treated with EPLBD only or in 
combination with the limited EST to remove CBD stones; and 
50 patients among these, who were available for follow-up 
with abdominal CTs for more than 6 months, were enrolled 
in the study.
Methods
Every endoscopy was performed by two experienced, more 
than 350 cases of annual ERCP volume, endoscopist (YS Kim 
or YS Ku), using side-viewing duodenoscopy (TJF-240; Olym-
pus Optical Co., Tokyo, Japan). All participants provided writ-
ten informed consent. Endoscopies were performed under 
conscious sedation by intravenous injection of midazolam (2-3 
mg) and fentanyl (100-150 µg) or by intravenous injection of 
midazolam (2-3 mg) plus intramuscular injection of meperi-
dine (25-50 mg), according to the endoscopists’ decision based 
on the patient’s age and weight. Ten milligram of cimetropium 
bromide was administered, if necessary, after reaching the des-
cending duodenum. After selective cannulation of the CBD, 
with cannula or pull-type papillotome, a cholangiogram was 
obtained to measure the stone size, CBD diameter, distal CBD 
angulation (CBD angle) and the length of the distal CBD arm. 
Limited EST was performed in patients without pervious EST 
experience; slightly extended EST was performed, if necessary, 
in patients with pervious EST experience. After inserting a 
guidewire, limited EST was performed by 1/3 of maximum 
incision of the papillary roof using standard pull-type papil-
lotome (MTW Endoskopie, Wesel, Germany). As the electro-
surgical unit, UES-30 (Olympus Optical Co.), with 40 W of 
blended current, consisted of repeating short cutting current 
and then coagulation current, was used. A 12-20 mm of bal-
loon catheter (controlled radial expansion balloon; Microva-
sive, Boston Scientific Co., Natick, MA, USA) was used ac-
cording to the endoscopists’ decision based on CBD diameter 
and stone size. The middle portion of the balloon was placed 
at the site of the biliary sphincterotomy; the balloon was grad-
ually inflated until achieving complete disappearance of its 
waist portion on cholangiogram under the fluoroscopic guid-
ance, immediately or maintained at least over 45 seconds af-
ter which the balloon was contracted; and then the stones were 
extracted using Dormia basket and retrieval balloon. A me-
chanical lithotripter was used when this procedure failed to 
extract the stones. In case of incomplete stone removal, en-
doscopic retrograde biliary drainage, followed by additional 
ERCP, were performed. Serum amylase and lipase were mea-
sured at 4 hours and 24 hours after removing the stones; liver 
function test and CBC were also performed, if necessary.
Outcome measurement and definitions
Pi-View PACS (Infinitt, Seoul, Korea) program was used for 
every measurement of sizes, lengths, and angles. Distal CBD 
angulation and the length of distal CBD arm were measured 
in accordance with the criteria proposed by Kim et al.
9 Periam-
pullary diverticulums (PAD) were categorized into 3 types 
based on the report by Lobo et al.
10 Complications were clas-
sified as suggested by Cotton et al.
11 and the stone recurrence 
was defined as the detection of a stone on CT images taken at 
least 6 months after confirming that the stone was completely 
removed on the final cholangiogram.
Statistical analysis
Kaplan-Meier method was used to analyze the association 
between risk factors and recurrence. Significant factors found 
in univariate analysis were analyzed in multivariate analysis 
with Cox regression to control confounding variables such as 
age and sex. Continuous variables were expressed as mean and 
standard deviation (SD). SPSS Windows version 12.0 (SPSS 
Inc., Chicago, IL, USA) statistical program was used for the an-
alysis and p<0.05 was considered to indicate statistical signific-
ance.
RESULTS
Patient characteristics 
The participants included 22 men (44.0%) with a mean±SD 
age of 67.4±14.4 years. Recurrence was confirmed in 12 (24.0%) 
out of 50 patients. The number of patients with previous cho-
lecystectomy and Billoth II gastrojejunostomy were 17 (34.0%) 
and 2 (4.0%), respectively. Twelve patients (24.0%) previously 
received endoscopic stone extraction with EST. PAD was fo-
und in 20 patients (40.0%); with type 1 in 2 patients (4.0%), 
type 2 in 12 patients (24.0%) and type 3 in 6 patients (12.0%). 
The mean follow-up period was 10.8±4.5 months, and the time 
to recurrence, among patients with recurrence, was 12.8±5.6 
months (Table 1). JH Kim et al. 
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Results of CBD stone removal with EPLBD 
The average maximum diameter (size) of CBD stones was 
13.8±4.3 mm, and multiple stones were found in 31 patients 
(62.0%). The average maximum diameter of the balloon cath-
eters used for the procedure was 16.0±2.4 mm; with 12 mm 
balloon catheter in 9 patients (18.0%), 15 mm in 17 patients 
(34.0%), 18 mm in 22 patients (44.0%) and 20 mm in 2 pa-
tients (4.0%). The maximum diameter of the dilated CBD was 
20.1±7.2 mm, the length of the distal CBD arm was 41.3±13.6 
mm, and distal CBD angle was 145.9±15.3°. Twenty patients 
(40.0%) received more than 2 ERCPs for stone removal, and 
1 patient (2.0%) received mechanical lithotripsy (Table 2).
Complications of EPLBD only or in combination 
with Limited EST 
 Mild pancreatitis occurred in 7 patients (14.0%) after ERCP, 
but severe pancreatitis was not reported. There was no hem-
orrhage or perforation as much as to require transfusion or to 
cause significant decrease in hemoglobin level (Table 3).
Risk factors of CBD stone recurrence 
A univariate analysis was performed, considering the fol-
low-up period, to identify risk factors of CBD stone recurr-
ence (Table 4). The result suggested that the previous chole-
cystectomy, concomitance of PAD and combination with EST 
were not statistically significant risk factors of recurrence, nor 
the presence of multiple stones. However, CBD stones ≥12 mm 
in diameter were found to be a statistically significant risk 
factor of recurrence (p=0.041). CBD angulation ≤145° was 
also found as a significant risk factor of recurrence (p=0.002), 
although the maximum CBD diameter of 15 mm or more and 
distal CBD arm of 36 mm or less were not found as statistically 
significant risk factors. The diameter of balloon catheters used 
for the procedure (≥18 mm) and the number of ERCPs per-
formed for stone removal (more than twice) were not signifi-
cant risk factors of recurrence either.
In multivariate analysis, CBD angulation ≤145° was found 
as the independent risk factor of recurrence (relative risk, 8.556; 
95% confidence interval [CI], 1.580-46.317; p=0.013), but not 
CBD stone more than 12 mm (Table 5).
 
DISCUSSION
ERCP and EST are regarded as a standard treatment to re-
Table 1. Characteristics at the Time of Intial ERCP in 50 Patients
Characteristic Value
Age, yr 67.4±14.4
Gender 
    Male
    Female
22 (44.0)
28 (56.0)
Previous surgery 
    Cholecystectomy
    Billoth II gastrojejunostomy
17 (34.0)
2 (4.0)
Previous ERCP 
    Previous EST 12 (24.0)
Baseline laboratory finding
    AST, IU/L
    ALT, IU/L
    ALP, IU/L
    Total bilirubin, mg/dL
141.9±206.6
120.5±131.3
171.6±112.8
3.7±4.6
Periampullary diverticulum 
    Type 1
a)
    Type 2
b)
    Type 3
c)
    Total
2 (4.0)
12 (24.0)
 6 (12.0)
20 (40.0)
Follow-up interval, mo  10.8±4.50
Values are presented as mean±SD or number (%).
ERCP, endoscopic retrograde cholangiopancreatography; EST, endo-
scopic sphncterotomy; AST, aspartate aminotransferase; ALT, ala-
nine aminotransferase; ALP, alkaline phosphatase. 
a)Papilla was located inside of diverticulum; 
b)Papilla was located at 
lower rim of diverticulum; 
c)Papilla was located outside of diverticu-
lum (<2 cm).
Table 2. Results of Endoscopic Stone Removal after EPLBD
Characteristic Value
CBD stone
Size of largest stone, mm
Multiple stones ≥2 
13.8±4.3
31 (62.0)
Diameter of balloon dilatation 
12 mm
15 mm
18 mm
20 mm
Total 
09 (18.0)
17 (34.0)
22 (44.0)
2 (4.0)
16.0±2.4
Characteristics of CBD
Largest bile duct diameter, mm
CBD arm, mm
CBD angle, degree
20.1±7.2
041.3±13.6
145.9±15.3
Complete stone removal in multiple (≥2) session  20 (40.0)
Mechanical lithotripsy performed  1 (2.0)
Values are presented as mean±SD or number (%).
EPLBD, endoscopic papillary large balloon dilation; CBD, com-
mon bile duct.
Table 3. Complications of EPLBD in 50 Patients
Complication No. (%)
Hemorrhage after ERCP 0 (0)
Perforation 0 (0)
Documented pancreatitis after ERCP 7 (14.0)
Total 7 (14.0)
EPLBD, endoscopic papillary large balloon dilation; ERCP, endoscopic 
retrograde cholangiopancreatography.126  Clin Endosc 2011;44:123-128
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place surgery in most cases of CBD stones.
1,2,5 Endoscopic pa-
pllirary balloon dilation (EPBD) without EST is often used 
for some patients with high bleeding tendency or when the 
function of Oddi sphincter is to be maintained.
12,13 The com-
bination therapy of EPLBD and EST has been reported, since 
its first report in 2003, to have relatively high success rate and 
low complication rate in various patient groups,
4,14 making it a 
suitable option when removing biliary stones not manageable 
with conventional EST.
15,16 
The recurrence of CBD stone is a serious late complication, 
which might cause recurrent cholangitis and secondary biliary 
cirrhosis, or even death due to sepsis when cholangitis was oc-
curred in old or immunocompromised patients. The recurr-
ence of CBD stones, after endoscopic extraction, occurs within 
3 years in most cases, at about 5% to 21% of frequency.
1,5-8 Di-
lated CBD, presence of PAD, history of previous cholecystec-
tomy and ≤145° of distal CBD angulation have been reported 
to be associated with recurrence so far.
5,6,17 Dilated CBD (>15 
mm) and history of previous cholecystectomy have been re-
ported as the risk factors of recurrence after EPBD.
18 There 
have been various reports on risk factors associated with CBD 
stone recurrence after EST,
1,5,6,17,19 but there are few studies 
yet on the risk factors of recurrence after stone removal with 
EPLBD. 
In this study, 12 mm or more maximum stone diameter and 
145° or less distal CBD angulation were found as significant 
factors in univariate analysis, and 145° or less distal CBD an-
gulation was found as an independent risk factor in multi-
variate analysis (relative risk, 8.556; 95% CI, 1.580-46.317; 
p=0.013). The presence of PAD was reported, in some stud-
ies, to be associated with stone production and recurrence, 
but other studies reported that there was no association be-
tween them.
11,20,21 The findings of this study suggested that the 
existence of PAD was not associated with the recurrence af-
ter removing stones with EPLBD, neither the type of PAD (data 
not shown). EPLBD seems more efficient, compared to EST, 
in treating difficult biliary stones with PAD, since it enables suf-
ficient distention of the major papillary orifice, which is why 
our study concluded that EPLBD would not cause any techni-
cal difficulty or affect the recurrence rate with or without PAD. 
Kim et al.
9 suggested 65 years or older age, history of gas-
trojejunostomy, short (≤36 mm) distal CBD arm and acute 
(≤135°) distal CBD angle as factors causing technical difficul-
ty in endoscopic removal of biliary stones. The current study, 
however, found that recurrence was not affected by the pa-
tient’s age, surgical history and length of distal CBD arm. The 
length of distal CBD arm may be regarded as an anatomical 
feature that might influence technical difficulty, as suggested 
in previous studies on recurrence after EST, but not as a con-
tributing factor to stone recurrence.
22
In our study, distal CBD angle of 135° or less was not found 
as a risk factor of stone recurrence, but distal CBD angle of 
145° or less found as an independent risk factor of stone re-
currence in the multivariate analysis, as reported by Keizman 
et al.
6 Distal CBD angle occurs naturally when CBD is curved 
to the right side before meeting the duodenum, and is con-
sidered to cause cholestasis.
6 It is reasonable to speculate that 
Table 4. Univariate Analysis of Risk Factors for Recurrent CBD Stones after EPLBD
Variable No recurrence (n=38) Recurrence (n=12) p-value
Patient-related factors 
Age ≥65
Male sex
Previous cholecystectomy
Previous EST
Periampullary diverticulum
Stone size ≥12 mm
Multiple stones ≥2
CBD diameter ≥15 mm
CBD arm ≤36 mm
Angulated CBD (angle ≤145°)
23 (60.5)
16 (42.1)
12 (31.6)
09 (23.7)
16 (42.1)
23 (60.5)
24 (63.2)
26 (68.4)
15 (39.5)
15 (39.5)
06 (50.0)
 06 (50.0)
 05 (41.7)
 03 (25.0)
 04 (33.3)
11 (91.7)
 07 (58.3)
11 (91.7)
 05 (41.7)
 08 (66.7)
0.914
0.836
0.740
0.403
0.917
0.041
0.706
0.195
0.361
0.002
Procedure related factors
Balloon diameter ≥18 mm
Multiple endoscopic session ≥2
17 (44.7)
15 (39.5)
07 (58.3)
05 (41.7)
0.213
0.781
Values are presented as number (%).
CBD, common bile duct; EPLBD, endoscopic papillary large balloon dilation; EST, endoscopic sphncterotomy.
Table 5. Multivariate Analysis of Risk Factors for Recurrent CBD 
Stones after EPLBD
Variable Relative risk (95% CI) p-value
Stone size ≥12 mm 5.998 (0.667-53.917) 0.110
Angulated CBD (angle ≤145°) 8.556 (1.580-46.317) 0.013
CBD, common bile duct; EPLBD, endoscopic papillary large bal-
loon dilation; CI, confidence interval.JH Kim et al. 
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bile stasis will become worse as the distal CBD angle becomes 
more acute, which is an important contributing factor of re-
currence, as confirmed in this study. Further studies in larger 
population is needed to find specific angle that increases the 
risk of recurrence. 
It is well known that bacterial colonization is increased wi-
thin the bile duct after EST. Extensive dilation of CBD (≥15 
mm) increases the likelihood of bacterial infection and cho-
lestasis after EST, acting as a risk factor of CBD stone recurr-
ence. However, maximal diameter of CBD was not found as a 
risk factor of recurrence in this study. Dilation of CBD often 
influences the recurrence rate in association with the size of 
the biliary stone, rather than by itself.
19 Therefore, EPLBD 
could easily remove stones of more than 15 mm in diameter, 
which explains why the stone recurrence was not affected by 
dilated CBD in this study. In case of mechanical lithotripsy, 
there have been reports that small remnant stones might cause 
biliary stone recurrence;
19 but we could not perform appro-
priate analysis with only 1 case of mechanical lithotripsy in the 
control group. Whether the lack of mechanical lithotripsy 
case, compared to the previous studies in South Korea on re-
currence after EST,
22 was due to the use of EPLBD only or in 
combination of limited EST, rather than EST only, or due to 
the small size of the study population of this study, is not clear; 
and more prospective studies are warranted in the future 
with this regard. Some studies have reported that larger CBD 
stones require more frequent mechanical lithotripsy, increas-
ing the likelihood of recurrence.
19 In this study, however, stone 
size was found as a significant risk factor only in the univari-
ate analysis, not in the multivariate analysis, suggesting that 
the stone size is not relevant to the recurrence. 
The number of patients who received ERCP more than twice 
and the rate of pancreatitis in this study were more increased 
compared to other studies, which may be explained by the 
fact that this study included patients unmanageable with con-
ventional EST.
It is generally difficult to conduct a long-term follow-up stu-
dy on CBD stone recurrence, because many of the recurrence 
cases are asymptomatic and these patients often miss the fol-
low-up visits voluntarily without much motivation for regu-
lar follow-up. Among patients who received EPLBD only or 
combination of EPLBD and limited EST in this study, only 
35.5% (50/141) of patients were available for regular follow-up 
with radiologic imaging, which may have introduced a selec-
tion bias as a limitation of this study. As the nature of retro-
spective studies, the fact that the mean follow-up period (10.8± 
4.5 months) was shorter than the mean time to recurrence 
(12.8±5.6 months), also worked as a limitation of this study to 
define risk factors of stone recurrence after the therapy.
Follow-up of CBD stone recurrence and identification of 
risk factors is essential when removing CBD stones using EP-
LBD only or in combination with limited EST. In clinical prac-
tice, high risk patients with identified risk factors should be 
regularly checked with imaging studies during the follow-up 
period, for early detection of stone recurrence and reduction 
of possible complications. 145° or less distal CBD angle was 
found, in this study, as an independent risk factor of CBD st-
one recurrence, and such patients may need to plan shorter fol-
low-up interval with regular imaging studies with or without 
symptoms.
In conclusion, 145° or less distal CBD angle on cholangio-
gram was found as an independent risk factor of CBD stone 
recurrence in patients treated with EPLBD only or in combi-
nation with limited EST, and regular follow-up is highly rec-
ommended in such patients with or without symptoms. How-
ever, further studies in larger populations are needed in the 
future due to the small size of this study population.
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